RegeneRx Biopharmaceuticals, Inc. filed its 10-K on Apr 11, 2023 for the period ending Dec 31, 2022. In this report its auditor, CohnReznick LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | 0.00% |
|
0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11K | |
+2.88% | 93.97B | |
+6.58% | 41.61B | |
-13.20% | 33.32B | |
+77.12% | 28.8B | |
-16.02% | 15.61B | |
-8.17% | 13.27B | |
-12.49% | 11.46B | |
+162.44% | 10.06B | |
-54.92% | 9.09B |
- Stock Market
- Equities
- RGRX Stock
- News RegeneRx Biopharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt